Learnings from cross-border biosimilar pricing policies in Europe
Expert Rev Pharmacoecon Outcomes Res
.
2024 Jun;24(5):585-588.
doi: 10.1080/14737167.2024.2334343.
Epub 2024 Mar 26.
Authors
Steven Simoens
1
,
Teresa Barcina Lacosta
1
,
András Inotai
2
3
Affiliations
1
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
2
Centre for Health Technology Assessment, Semmelweis University, Budapest, Hungary.
3
Syreon Research Institute, Budapest, Hungary.
PMID:
38530083
DOI:
10.1080/14737167.2024.2334343
No abstract available
Keywords:
Biosimilar; europe; policy; price; procurement; sustainability.
Publication types
Editorial
MeSH terms
Biosimilar Pharmaceuticals* / economics
Costs and Cost Analysis
Drug Costs*
Europe
Humans
Substances
Biosimilar Pharmaceuticals